Johnson & Johnson (JNJ)

Health Care·equity
$260.78
+1.68% today
Prices delayed about 15 minutes · cached page, can be an hour old or more
Tapeline Score
58/ 100
Score level
Above average
6 of 6 checks had data

Business numbers score (revenue, margins, returns) is near the top of its range, with price trend score is on the high side.

JNJ scores higher than 83% of the 1,101 tickers we compare it with (Health Care).

As of 9 October 2026, Johnson & Johnson (JNJ) scores 58 out of 100 on the Tapeline six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.

Updated · scores usually change about once a day

TrendStrengthFinancialsInsidersMarketMomentum58/ 100

Key statistics

Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.

Relative volume
0.33× 30-day average
52-week range
184.66 – 281.07
Market cap
$650.65B
Earnings date
13 Oct 2026
Dividend yield
3.12%
Volume
2,213,960
Avg. volume (30d)
6,661,331
Open
255.09
Previous close
256.48
Day's range (regular session)
254.99 – 261.39

The last trade can be an extended-hours trade, so it can sit outside the regular-session range.

Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.

Beta
0.20
P/E (TTM)
29.01
EPS (TTM)
8.62

Score breakdown · six named factors

Price trend
71
Strength vs the market
56
Company finances
80
Insider trades
32
Market mood
50
Recent momentum
50

Each bar is one part of the score, from 0 to 100. Read what the score means.

Premium data held for JNJ

  • 17 SEC Form 4 insider transactions in the last 90 daysPremium

Counts of rows Tapeline holds for JNJ. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans

What the score says about JNJ right now

Johnson & Johnson (JNJ) currently scores 58/100 on the Tapeline six-factor composite, at the Above average score level. JNJ is +1.68% on the day and -0.84% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for JNJ leans good, with some weak spots. JNJ's strongest factor is company finances at 80/100 — a very strong read on the company's own reported numbers. A high reading doesn't promise a near-term move. The weakest factor is insider trades at 32/100 — a below average read on insider buying and selling. Insider filings for JNJ lean toward selling; on a thinly filed name a few filings can set this reading.

Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.

See JNJ in the scanner

This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).

Recent JNJ news

Latest headlines that name Johnson & Johnson, one per story, sourced from Tapeline’s news feed (Polygon/Massive + Finnhub).

We hide 6 more that told readers to buy or sell, or gave a price target.

Saved snapshot; the news and prices on this page can be an hour old or more.

Similar setups in Health Care right now

Six health care tickers whose composite scores are closest to JNJ’s 58, all within 1 point.

Sorted by closeness to JNJ’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →

Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.